CRISPR lung cancer trial pulled before it even started
NCT ID NCT05566223
First seen Mar 17, 2026 · Last updated May 15, 2026 · Updated 7 times
Summary
This trial aimed to test a new treatment for people with metastatic non-small cell lung cancer. Doctors would take immune cells from a patient's tumor, use CRISPR gene editing to make them stronger, and then put them back into the patient. The goal was to see if these edited cells could shrink tumors or slow the cancer. However, the study was withdrawn before any patients were enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Comprehensive Cancer Center
Duarte, California, 91010, United States
-
Masonic Cancer Center, University of Minnesota
Minneapolis, Minnesota, 55455, United States
Conditions
Explore the condition pages connected to this study.